Analysis promising for keratectasia

Article

Diagnostic platform combines anterior surface topography, corneal tomography data

An analysis combining information from anterior Placido topography and corneal tomography obtained using a proprietary corneal imaging diagnostic platform (Orbscan II, Bausch + Lomb) has shown high sensitivity and specificity for discriminating between Placido negative eyes with forme fruste keratoconus (FFKC) and normal controls, and shows promise as a clinically useful tool for early diagnosis of keratectasia, said Dr Damien Gatinel, PhD.

"Our investigation shows that in eyes where there is no suspicion of keratoconus based on objective analysis of the anterior topography, evaluation of corneal tomography data may sometimes reveal an underlying ectatic condition," he added.

"Answering the question of what technique is superior for early detection of keratectasiasusceptible corneas requires welldesigned investigations. These must use a pertinent clinical model and appropriate statistical methods," Dr Gatinel said.

"These studies must include corneas with known keratectasia susceptibility, and to achieve maximum specificity and sensitivity, they must use discriminant analysis that evaluates the method's performance in separating the study groups and so minimizes false negatives and false positives," he explained.

Borrowing from Dr Stephen D. Klyce, PhD, who stated that the fellow eye of a patient with unilateral keratoconus should be considered as having FFKC, Dr Gatinel suggested that the fellow 'normal' represents the perfect false negative model for discriminant analysis studies.

"As Dr Klyce said, although the FFKC eye has no clinical findings of keratoconus and is Placido negative, it has genetic susceptibility to keratoconus and is considered to have subclinical keratoconus," he said.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.